Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2026

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )
18 Jun 2026

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )
18 Jun 2026

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )
18 Jun 2026

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )
18 Jun 2026

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Prof David Kuter - Harvard Medical School, Boston, USA
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )
18 Jun 2026

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia

Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia ( Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark )
18 Jun 2026

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026